{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-072931","form_type":"8-K","ticker":"XAGE","cik":"0001842939","company_name":"Longevity Health Holdings, Inc.","filed_at":"2025-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.094685+00:00","generated_at":"2026-05-21T03:35:53.413097+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Longevity Health Q1 pro forma sales $663k, merger with 20/20 BioLabs progressing","bullets":["XAGE Q1 unaudited pro forma sales ~$663k (+8% YoY); 20/20 sales ~$562k (+15% YoY).","Merger agreement with 20/20 signed April 11; S-4 filed May 8; closing subject to conditions.","1-for-30 reverse stock split completed May 12; trading at split-adjusted price from May 14.","Expected Q2 launches: XAGE medicated cleanser, 20/20 inflammatory biomarker test, and OneTest pilot with Giant Food.","Company evaluating options for additional financing, anticipates primary investment in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-072931","json":"https://secwatch.observer/filing/0000950170-25-072931.json","markdown":"https://secwatch.observer/filing/0000950170-25-072931.md","text":"https://secwatch.observer/filing/0000950170-25-072931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842939/000095017025072931/0000950170-25-072931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842939/000095017025072931/xage-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T03:35:53.413097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}